XBXue Bao

Xue Bao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xue Bao has a total of 48 co-authors. Here are the top co-authors by number of shared publications:

  • Biao Xu

    Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, No. 321 Zhongshan Road, Nanjing 210008, China

    6 shared publications
  • Rong Gu

    Nanjing University

    3 shared publications
  • Heyu Chu

    Department of Cardiology Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University Nanjing China

    2 shared publications
  • Kun Wang

    Department of Cardiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China

    2 shared publications
  • Lina Kang

    Department of Cardiology, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School

    2 shared publications
  • Xi Tan

    Department of Cardiology Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China

    2 shared publications

Latest Publications

  • Open Access

    Exploratory predictive value of novel inflammatory biomarkers for microvascular obstruction after emergency revascularization in STEMI patients

    by Yang Dai, Longjin Chen, Zhe Zhang, Kaleem Ullah Shahzad, Qing Dai, Ying Tan, Xue Bao, Lina Kang, Biao Xu

    Purpose: To assess the associations of blood cell-derived inflammatory markers with the formation of microvascular obstruction (MVO) and their exploratory predictive performance in STEMI patients after PCI. Patients and methods: A retrospective analysis was conducted based on a prospective cohort, which included the patients with ST-segment elevation myocardial infarction (STEMI) who underwent emergency percutaneous coronary intervention (PCI) at Nanjing Drum Tower Hospital. All patients underwent cardiac magnetic resonance imaging within 7 days post-surgery, and were classified into MVO and non-MVO groups based on the examination results. Emergency and first post-PCI routine blood test and other clinical data were collected from patients, and various cell ratios were calculated, including the monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), systemic inflammatory response index (SIRI), and aggregate index of systemic inflammation (AISI). The risk factors for MVO were evaluated by univariate and multivariate logistic regression analysis. Results: A total of 311 patients with STEMI were included. Among them, 198 developed MVO and the other 113 were MVO free. After adjustment for clinical covariates, higher post-PCI WBC, NEU, SIRI and NLR and greater peri-PCI eosinophil decline were associated with MVO. In the correlation-reduced joint analysis, post-PCI SIRI retained the most robust association. Conclusion: Postoperative WBC, NEU, SIRI, NLR, Δ EOS, Δ EOS% showed exploratory predictive performance for the formation of MVO after PCI in STEMI patients, and post-PCI SIRI showed the most robust association after accounting for biomarker intercorrelation.

  • Open Access

    Association Between F‐SIRI and Adverse Prognosis in Patients With Chronic Heart Failure

    by Xiaoli Liu, Heyu Chu, Guo Song, Yi Wang, Junfeng Duan, Xi Tan, Xue Bao, Biao Xu, Rong Gu

    Aims: High plasma fibrinogen and systemic inflammation response index (F‐SIRI) has been proposed as a novel prognostic factor in resectable gastric cancer. However, available data on the prognostic value of F‐SIRI in chronic heart failure (CHF) patients is limited. We aimed to conduct a retrospective cohort study exploring the correlation between F‐SIRI and prognosis in CHF individuals. Methods: We consecutively enrolled 1589 hospitalized patients (aged 66 ± 8 years, 32.9% women) with CHF from January 1, 2019 to August 31, 2022 in this single‐center retrospective study. SIRI was calculated with the formula (monocyte count*neutrophil count/lymphocyte count). The primary endpoints encompassed all‐cause death, the major adverse cardiac and cerebral events (MACCEs) and cardiovascular death. The association between F‐SIRI and the risk of developing adverse outcomes were explored using four multivariate‐adjusted Cox proportional hazard models. Results: During a median follow‐up of 687 days, 207 all‐cause deaths, 462 MACCEs and 136 cardiovascular deaths were recorded. After adjusting for potential confounding factors, only risk of all‐cause death remained significantly associated with higher levels of F‐SIRI. The hazard ratios (HRs) for the highest F‐SIRI group (F‐SIRI = 2) versus the lowest F‐SIRI group (F‐SIRI = 0) were 2.37 (95% confidence interval [CI], 1.46−3.83; p < 0.001) for all‐cause death. The addition of F‐SIRI could increase the prognostic ability for all‐cause death on the basis of traditional risk factors. Conclusions: F‐SIRI is a significant predictor of all‐cause death but has limited predictive value for MACCEs and cardiovascular death in CHF patients.


  • Open Access

    Mediation effect analysis of lipoprotein levels on BMI and cardiovascular outcomes in patients with heart failure

    by Yi Wang, Xiaoli Liu, Baochuan Wu, Xi Tan, Lin Chen, Heyu Chu, Zeyu Zhou, Xue Bao, Biao Xu, Rong Gu

    Among heart failure patients with obesity, the prognosis is better than those with normal weight, a phenomenon known as the obesity paradox. However, it is unclear whether lipoprotein levels play a mediating role in the machine of the obesity paradox. The study included 1663 heart failure patients hospitalized from January, 2019 through August, 2022. Kaplan-Meier survival analysis and Log-rank tests were performed for three endpoints in order to determine cumulative event-free survival. We investigated the correlation between Body Max Index (BMI) and outcomes by multifactorial Cox models. Mediation analysis was applied to study the presence and magnitude of mediation effects of triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B, with the association between BMI and endpoints. In MACCEs, the median follow-up period was 679 days. In Cox model, compared with the underweight group, a high BMI level was significantly associated with lower all-cause mortality (HR=0.47, 95%CI 0.31~0.69, p<0.001, obese vs underweight), cardiovascular mortality (HR=0.46, 95%CI 0.30~0.73, p<0.001, obese vs underweight) and the incidence of MACCEs (HR=0.68, 95%CI 0.53~0.88, p=0.003, obese vs underweight). Mediation analysis revealed that TG was the strongest mediator between BMI and endpoints, with proportions of mediated effects of 6.6% (95%CI 2.2%~18.0%, p=0.0258, in all-cause death),7.0% (95%CI 2.3%~18.9%, p=0.0301, in cardiovascular death) and 10.2% (95%CI 3.3%~27.4%, p=0.0185, in MACCEs). There is an "obesity paradox" in patients with heart failure, and lipoprotein levels especially triglyceride mediate the association between BMI and cardiovascular outcomes.


  • Open Access

    Colchicine Attenuates Microvascular Obstruction after Myocardial Ischemia-Reperfusion Injury by Inhibiting the Proliferation of Neutrophil in Bone Marrow

    by Ying Tan, Xue Bao, Yuyu Li, Guo Song, He Lu, Xuan Sun, Rong Gu, Lina Kang, Biao Xu

    Purpose: Complete and rapid recanalization of blood flow by percutaneous coronary intervention (PCI) is the most effective intervention for patients with ST-segment elevation myocardial infarction (STEMI). However, myocardial ischemia/reperfusion (I/R) injury leads to microvascular obstruction (MVO), limiting its efficacy. Colchicine can reduce myocardial I/R injury, but its effect on MVO is unclear. Hence, this study aimed to assess the role and mechanism of colchicine on MVO. Methods: Clinical data on STEMI patients with PCI were collected and risk factors related to MVO were analyzed. The rat myocardial I/R model was established to evaluate the MVO by thioflavin S staining. The myocardial I/R model of mice was treated with PBS or colchicine at the reperfusion. The effect of colchicine on cardiomyocyte apoptosis after I/R was evaluated by TUNEL and expression of cleaved caspase-3. ROS levels were detected in H9c2 cells to evaluate the colchicine effect on myocardial oxidative stress. Moreover, the mechanism through which colchicine attenuated MVO was examined using flow cytometry, WB, ELISA, immunohistochemistry, bioinformatics analysis, and immunofluorescence. Results: Multivariate analysis showed that elevated neutrophils were associated with extensive MVO. Colchicine could attenuate MVO and reduce neutrophil recruitment and NETs formation after myocardial I/R. In addition, colchicine inhibited cardiomyocyte apoptosis in vivo and ROS levels in vitro. Furthermore, colchicine inhibited neutrophil proliferation in the bone marrow (BM) by inhibiting the S100A8/A9 inflammatory signaling pathway. Conclusions: Colchicine attenuated MVO after myocardial I/R injury by inhibiting the proliferation of neutrophils in BM through the neutrophil-derived S100A8/A9 inflammatory signaling pathway.


  • Platelet mitochondrial DNA methylation: A novel biomarker for myocardial infarction – A preliminary study

    by Ningxin Peng, Liqiong Guo, Zhonghai Wei, Xiao Wang, Lei Zhao, Lina Kang, Kun Wang, Weihong Zhou, Shoujun Cheng, Songjiang Yin, et al.


  • Open Access

    Predictive Value of Fasting Blood Glucose for Microvascular Obstruction in Nondiabetic Patients with ST-Segment Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention

    by Han Wu, Ran Li, Kun Wang, Dan Mu, Jian-Zhou Chen, Xuan Wei, Xue Bao, Zhong-Hai Wei, Jun Xie, Biao Xu

    Background. The relationship between fasting blood glucose (FBG) and microvascular obstruction (MVO) after primary percutaneous coronary intervention (PCI) remains unclear in nondiabetic patients with ST-segment elevation myocardial infarction (STEMI). This study aimed to determine the predictive value of FBG in MVO in nondiabetic STEMI patients. Methods. A total of 108 nondiabetic STEMI patients undergoing primary PCI were enrolled in this study. The patients were classified into either the MVO group or non-MVO group based on cardiac magnetic resonance imaging (CMR). Results. FBG in the MVO group was higher than in the non-MVO group. Univariate analysis showed that FBG, peak high-sensitive troponin T (TnT), pre-PCI thrombolysis in myocardial infarction (pre-PCI TIMI) flow, left ventricular ejection fraction (LVEF), infarction size, left ventricular end-diastolic diameter (LVEDd), left ventricular end-diastolic volume (LVEDV), and global longitudinal strain (GLS) were likely predictive factors of MVO. After adjustment for other parameters, FBG, peak TnT, LVEF, and LVEDV remained independent predictors for MVO. Conclusion. FBG was independently associated with MVO in nondiabetic STEMI patients.


  • Open Access

    Comparing the inflammatory profiles for incidence of diabetes mellitus and cardiovascular diseases: a prospective study exploring the ‘common soil’ hypothesis

    by Xue Bao, Yan Borné, Linda Johnson, Iram Faqir Muhammad, Margaretha Persson, Kaijun Niu, Gunnar Engström

    Chronic low-grade inflammation and associated insulin resistance and metabolic abnormalities have been proposed as ‘common soil’ for diabetes mellitus (DM) and cardiovascular disease (CVD). This paper aimed to investigate the inflammatory profiles of DM and CVD and to distinguish their shared and specific markers. Based on the Malmö Diet and Cancer cohort, total and differential leukocyte counts were measured in 25,969 participants without previous DM or CVD and were studied in relation to incident DM (mean follow-up 17.4 ± 5.58 years) and incident CVD (i.e., coronary events, including fatal and nonfatal myocardial infarction, or stroke); mean follow-up 17.7 ± 5.46 years, using multivariable Cox regression models. Furthermore, plasma concentrations of another seven inflammatory markers were examined in relation to incident DM and incident CVD in a sub-cohort of 4658 participants. The associations of each inflammatory marker with incident DM versus incident CVD were compared using the Lunn–McNeil competing risks approach. In sensitivity analyses, those who developed both DM and CVD during follow-up were excluded. After adjustment for conventional risk factors, total and differential leukocyte counts, orosomucoid, and C-reactive protein were associated with an increased risk of both DM and CVD. Neutrophil to lymphocyte ratio, ceruloplasmin, alpha1-antitrypsin and soluble urokinase plasminogen activator receptor predicted increased risk of CVD but not DM, while haptoglobin and complement C3 showed the opposite pattern. In competing risks analyses, lymphocyte count and complement C3 had stronger associations with risk of DM than with risk of CVD (p for equal associations = 0.020 and 0.006). The reverse was true for neutrophil to lymphocyte ratio (p for equal associations = 0.025). Results were consistent in sensitivity analyses. The results indicated substantial similarities in the inflammatory profiles associated with DM and CVD. However, there are also significant differences. These findings may help discriminate between individuals at elevated risk of DM and those at elevated risk of CVD, which is a prerequisite for targeted therapies.